sinc
discov
middl
east
respiratori
syndrom
coronaviru
merscov
caus
agent
sever
respiratori
ill
middl
east
serolog
test
conduct
assess
antibodi
respons
patient
investig
zoonot
reservoir
viru
although
viru
neutral
test
gold
standard
assay
mer
diagnosi
investig
zoonot
reservoir
use
live
viru
must
perform
high
contain
laboratori
competit
elisa
celisa
label
monoclon
antibodi
mab
compet
test
serum
antibodi
target
epitop
may
suitabl
altern
detect
antibodi
speciesindepend
manner
studi
novel
mab
spike
protein
merscov
produc
character
one
mab
use
develop
celisa
celisa
detect
merscovspecif
antibodi
sera
merscovinfect
rat
rabbit
immun
spike
protein
merscov
mabbas
celisa
valid
use
sera
ethiopian
dromedari
camel
rel
neutral
test
celisa
detect
merscovspecif
antibodi
ethiopian
dromedari
camel
sensit
specif
respect
celisa
neutral
test
result
correl
well
pearson
correl
coeffici
depend
celisa
serum
dilut
celisa
may
use
mer
epidemiolog
investig
merscov
infect
http
dx
middl
east
respiratori
syndrom
mer
respiratori
diseas
human
caus
lineag
c
betacoronaviru
name
merscoronaviru
merscov
first
identifi
middl
east
patient
mer
live
outsid
endem
region
histori
travel
temporari
resid
middl
east
also
identifi
de
groot
et
al
date
least
laboratoryconfirm
case
mer
report
case
fatal
rate
cfr
patient
show
sever
symptom
high
cfr
mild
asymptomat
case
report
mer
outbreak
humantohuman
transmiss
merscov
rel
limit
compar
outbreak
sever
acut
respiratori
syndrom
sar
algethami
et
al
drosten
et
al
memish
et
al
observ
report
support
crosssect
studi
saudi
arabia
show
decemb
healthi
popul
antimerscov
antibodi
muller
et
al
sever
studi
show
middl
east
human
infect
merscov
direct
indirect
contact
dromedari
camel
indic
dromedari
camel
implic
amplifi
host
merscov
strong
potenti
sourc
zoonot
infect
al
hammadi
et
al
merscov
research
furthermor
merscov
appear
circul
outsid
middl
east
sinc
viru
detect
dromedari
camel
east
west
north
africa
reusken
et
al
sinc
batcoronavirus
btcov
detect
tylonycteri
pipistrellu
bat
respect
close
relat
merscov
bat
may
suspect
natur
host
merscov
lu
liu
howev
clear
whether
merscov
transmit
bat
camel
anim
speci
identifi
zoonot
reservoir
merscov
determin
crossspeci
transmiss
merscov
occur
serolog
assay
detect
merscov
antibodi
sera
variou
anim
speci
need
assay
could
also
use
systemat
epidemiolog
surveil
middl
eastern
commun
clarifi
whether
asymptomat
infect
occur
via
humantohuman
transmiss
prefer
screen
tool
detect
serum
antibodi
pathogen
immunofluoresc
assay
ifa
convent
enzymelink
immunosorb
assay
elisa
howev
use
assay
term
detect
antimerscov
antibodi
limit
fact
antibodi
conserv
protein
coronavirus
often
crossreact
result
assay
often
yield
falseposit
reaction
chen
et
al
corman
et
al
meyer
et
al
neutral
assay
plaqu
reduct
neutral
test
micropl
neutral
test
set
use
suscept
cell
line
live
merscov
neutral
assay
consid
gold
standard
detect
measur
serum
antibodi
respons
merscov
highli
specif
sensit
hemida
et
al
perera
et
al
reusken
et
al
howev
assay
requir
high
contain
laboratori
due
use
highli
pathogen
live
merscov
altern
neutral
assay
base
replicationincompet
pseudoparticl
gener
use
vesicular
stomat
viru
vsv
human
immunodefici
viru
type
develop
safe
highthroughput
neutral
test
fukuma
et
al
hemida
et
al
perera
et
al
addit
cellfre
protein
microarray
use
fragment
merscov
protein
antigen
develop
reusken
et
al
possibl
type
test
yet
report
merscov
field
competit
elisa
celisa
celisa
employ
label
monoclon
antibodi
mab
compet
test
antibodi
target
antigen
use
wide
serolog
surveil
human
veterinari
medicin
blomstrom
et
al
chand
et
al
houlihan
et
al
moreno
et
al
signific
advantag
convent
elisa
ifa
name
detect
antibodi
specif
target
antigen
anim
includ
human
present
studi
develop
celisa
detect
antimerscov
antibodi
main
idea
neutral
respons
test
serum
determin
celisa
label
mab
use
celisa
recogn
neutral
epitop
merscov
antigen
thu
novel
mab
neutral
activ
merscov
produc
character
celisa
use
one
mab
develop
celisa
valid
use
sera
taken
dromedari
camel
also
compar
neutral
test
hela
vero
cell
obtain
american
type
cultur
collect
vero
cell
express
shirato
et
al
maintain
dmem
sigmaaldrich
st
loui
mo
supplement
heatinactiv
fetal
bovin
serum
fb
murin
myeloma
cell
line
maintain
medium
sigmaaldrich
supplement
heatinactiv
fb
hybridoma
cell
maintain
hat
medium
gibco
thermofish
scientif
rockford
il
sera
heat
inactiv
min
gener
valid
celisa
three
posit
control
sera
neg
control
sera
use
three
posit
control
two
rabbit
immun
recombin
merscov
rat
infect
merscov
fukuma
et
al
iwatayoshikawa
et
al
neg
control
sera
ten
mice
immun
recombin
sarscov
protein
ishii
et
al
two
rabbit
immun
recombin
merscov
n
protein
fukuma
et
al
rabbit
immun
recombin
sarscov
protein
fukuma
et
al
rabbit
immun
uvinactiv
sarscov
particl
fukushi
et
al
four
mockinfect
rat
nonimmun
mice
healthi
human
donor
sinc
expect
sera
multipl
anim
speci
could
appli
celisa
neg
control
serum
sampl
use
determin
cutoff
valu
celisa
sera
collect
dromedari
camel
awash
river
basin
ethiopia
use
valid
celisa
transport
conduct
permiss
japanes
govern
anim
quarantin
inspect
number
follow
rule
regul
oiefao
biolog
sampl
transport
merscov
cultur
laboratori
nation
institut
infecti
diseas
describ
previous
iwatayoshikawa
et
al
vero
cell
inocul
merscov
multipl
infect
moi
per
cell
h
cell
lyse
pb
contain
extract
viral
antigen
infect
cell
iwatayoshikawa
et
al
centrifug
min
supernat
collect
use
merscov
antigen
celisa
antigen
inactiv
uv
irradi
nm
mwcm
transillumin
min
use
viral
inactiv
confirm
complet
use
inocul
antigen
vero
cell
follow
cultiv
cell
least
week
gener
hybridoma
balbc
mice
immun
merscov
particl
purifi
cultur
supernat
follow
vero
cell
inocul
merscov
moi
day
cultur
supernat
fraction
collect
mix
polyethylen
glycol
nacl
centrifug
min
precipit
viral
particl
precipit
dissolv
pb
appli
sucros
cushion
subject
ultracentrifug
rpm
h
use
rotor
interphas
fraction
sucros
layer
collect
ultracentrifug
step
repeat
purifi
viru
particl
interphas
fraction
sucros
layer
collect
use
antigen
immun
merscov
particl
inactiv
uv
irradi
viral
inactiv
confirm
complet
describ
balbc
mice
first
immun
subcutan
purifi
merscov
particl
emulsifi
complet
freund
adjuv
sigmaaldrich
second
third
immun
purifi
merscov
dissolv
pb
administ
intraven
hybridoma
produc
fuse
cell
splenic
cell
mice
obtain
day
last
immun
cultur
supernat
hybridoma
cell
screen
presenc
antibodi
merscov
antigen
elisa
describ
previous
iwatayoshikawa
et
al
exclud
hybridoma
produc
antibodi
crossreact
coronavirus
cultur
supernat
also
subject
elisa
use
antigen
prepar
cell
infect
human
coronaviru
kindli
provid
dr
shutoku
matsuyama
niid
elisa
also
perform
describ
previous
iwatayoshikawa
et
al
mabproduc
hybridoma
cell
react
specif
merscov
select
clone
use
limit
dilut
method
isotyp
mab
determin
use
mous
monoclon
antibodi
isotyp
kit
abd
serotec
kidlington
uk
mab
purifi
cultur
supernat
use
protein
g
column
chromatographi
mabtrap
kit
ge
healthcar
uk
ltd
buckinghamshir
uk
accord
manufactur
instruct
concentr
purifi
mab
determin
use
pierc
bca
protein
assay
reagent
thermo
fisher
scientif
verifi
specif
mab
rbd
merscov
sarscov
protein
prepar
use
baculoviru
express
system
describ
previous
fukuma
et
al
briefli
nucleotid
sequenc
encod
amino
acid
protein
merscov
amino
acid
protein
sarscov
tag
cterminu
histidinetag
clone
transfer
vector
insect
cell
transfect
mixtur
transfer
vector
bd
baculogold
linear
baculoviru
dna
bd
bioscienc
san
jose
ca
accord
manufactur
instruct
thu
produc
merscov
rbdexpress
baculoviru
acmersrbdhi
sarscov
rbdexpress
baculoviru
acsarsrbdhi
insect
cell
infect
acmersrbdhi
acsarsrbdhi
thu
produc
merscov
rbd
sarscov
rbd
respect
three
day
post
infect
rbd
protein
purifi
cultur
supernat
use
ni
nitrilotriacet
acid
affin
chromatographi
qiagen
hilden
germani
accord
manufactur
instruct
rbd
protein
use
convent
elisa
briefli
elisa
plate
thermo
fisher
scientif
coat
ng
purifi
rbd
protein
iggelisa
perform
describ
previous
iwatayoshikawa
et
al
determin
whether
mab
recogn
rbd
merscov
protein
also
recogn
rbd
coronavirus
express
plasmid
encod
mous
fctag
rbd
merscov
kindli
suppli
prof
georg
gao
institut
microbiolog
chines
academi
scienc
beij
pr
china
use
hela
cell
transfect
express
plasmid
h
cell
fix
methanolaceton
mab
label
fitc
use
fluorescein
label
dojindo
kumamoto
japan
fluoresc
signal
fix
cell
observ
fluoresc
microscop
alexa
fluor
antimous
igg
antibodi
thermo
fisher
scientif
serv
posit
control
detect
mous
fctag
rbd
protein
neutral
assay
base
live
merscov
perform
describ
previous
fukushi
et
al
shirato
et
al
briefli
vero
cell
shirato
et
al
cultur
plate
inocul
merscov
premix
seriallydilut
serum
sampl
cytopath
effect
cpe
vero
cell
observ
day
day
postinfect
respect
neutral
titer
determin
reciproc
highest
dilut
show
least
cpe
plaquereduct
assay
approxim
plaqueform
unit
pfu
merscov
mix
seriallydilut
mab
incub
h
vero
cell
cultur
plate
inocul
mixtur
day
cell
fix
formalin
stain
crystal
violet
plaqu
count
reduct
rate
compar
induc
mab
control
unrel
mab
mab
use
neg
control
approxim
pfu
merscov
mix
mab
vero
cell
grown
plate
inocul
mixtur
cultur
supernat
harvest
day
post
infect
vero
cell
grown
plate
inocul
virus
escap
mab
neutral
escap
mutant
purifi
use
agaroseoverlay
plaqu
assay
three
five
escap
mutant
clone
obtain
mab
viral
rna
extract
cultur
supernat
vero
cell
infect
escap
mutant
nucleotid
sequenc
gene
determin
celisa
perform
follow
whole
merscov
antigen
coat
elisa
plate
overnight
optim
concentr
determin
beforehand
data
shown
well
wash
incub
pb
contain
bovin
serum
albumin
block
reagent
h
remov
block
reagent
well
incub
h
biotinlabel
mab
mix
serial
dilut
serum
sampl
wash
well
incub
h
streptavidinhrp
thermo
fisher
scientif
wash
well
incub
min
room
temperatur
abt
cutoff
valu
serum
dilut
calcul
mean
plu
three
standard
deviat
percent
inhibit
serum
dilut
neg
control
sampl
thu
cutoff
valu
serum
dilut
inhibit
respect
pearson
correl
coeffici
calcul
use
graphpad
prism
softwar
anim
studi
perform
accord
protocol
approv
anim
care
use
committe
nation
institut
infecti
diseas
japan
serum
sampl
healthi
human
donor
collect
use
indic
experi
accord
protocol
procedur
approv
research
ethic
committe
nation
institut
infecti
diseas
obtain
mab
specif
merscov
balbc
mice
immun
purifi
uvinactiv
merscov
particl
hybridoma
gener
clone
elisa
use
determin
whether
mab
secret
hybridoma
recogn
whole
merscov
antigen
human
coronavirus
name
mab
seven
identifi
merscov
specif
supplementari
fig
limit
possibl
crossreact
coronavirus
assess
whether
seven
mab
specif
recogn
merscov
antigen
protein
coronavirus
diverg
coronaviru
protein
thu
perform
ifa
merscov
proteinexpress
cell
found
five
mab
react
protein
merscov
n
protein
supplementari
fig
addit
determin
whether
seven
mab
could
neutral
merscov
infect
perform
viral
neutral
assay
use
replicationincompet
vsv
express
merscov
protein
supplementari
fig
three
proteinspecif
mab
design
show
neutral
activ
three
mab
react
receptorbind
domain
rbd
merscov
protein
rbd
protein
coronavirus
name
sarscov
fig
fig
isotyp
mab
kappa
isotyp
plaqu
reduct
assay
concentr
inhibit
merscov
infect
respect
fig
approxim
pfu
merscov
mix
serial
dilut
purifi
mab
mixtur
use
inocul
vero
cell
cultur
plate
day
cell
fix
formalin
stain
crystal
violet
viral
titer
express
pfu
rel
viral
titer
absenc
antibodi
unrel
mab
mab
serv
neg
control
target
put
epitop
three
mab
determin
sequenc
gene
variant
virus
escap
neutral
mab
critic
amino
acid
residu
requir
bind
mab
mab
mab
identifi
fig
accord
structur
rbd
merscov
protein
complex
human
receptor
molecul
ying
et
al
critic
residu
locat
site
protein
fig
fact
put
epitop
three
mab
locat
site
rbd
suggest
mab
may
inhibit
entri
merscov
block
interact
merscov
rbd
epitop
like
overlap
amino
acid
substitut
escap
mutant
close
fig
inde
two
merscov
mutant
escap
neutral
ie
grew
effici
presenc
similarli
two
merscov
mutant
escap
neutral
ie
replic
well
presenc
contrast
mab
strongli
neutral
escap
mutant
addit
mab
effect
neutral
escap
mutant
fig
thu
mutant
virus
escap
also
escap
vice
versa
indic
epitop
two
mab
overlap
sequenc
analysi
heavi
light
chain
gene
reveal
sever
amino
acid
differ
variabl
region
includ
complementari
determin
region
supplementari
fig
celisa
develop
use
three
mab
establish
studi
abil
rabbit
merscov
proteinspecif
antibodi
compet
mab
merscov
antigen
test
celisa
increas
concentr
rabbit
serum
steadili
decreas
bind
mab
antigen
supplementari
fig
contrast
serum
rabbit
immun
merscov
n
protein
slightli
inhibit
bind
mab
supplementari
fig
thu
celisa
use
three
mab
could
detect
antimerscov
antibodi
mab
particularli
effect
celisa
show
high
sensit
low
background
nois
supplementari
fig
consequ
select
examin
optim
celisa
celisa
test
serum
sampl
rat
infect
merscov
two
rabbit
immun
recombin
merscov
protein
rabbit
immun
recombin
merscov
n
protein
sar
protein
uvinactiv
sarscov
particl
serum
merscovinfect
rat
rabbit
sera
specif
recombin
merscov
protein
strongli
inhibit
bind
wherea
serum
sampl
rabbit
immun
recombin
merscov
n
protein
recombin
sarscov
protein
uvinactiv
sarscov
particl
effect
serum
uninfect
rat
also
effect
fig
thu
celisa
may
use
detect
serum
antimerscov
antibodi
experiment
anim
model
fig
sinc
serum
sampl
collect
dromedari
camel
ethiopia
reactiv
antigen
merscov
reusken
et
al
test
whether
celisa
could
also
accur
detect
dromedari
camel
serum
sampl
posit
antimerscov
antibodi
determin
neutral
assay
thu
perform
celisa
serum
sampl
collect
dromedari
camel
ethiopia
cutoff
valu
celisa
determin
use
neg
control
sera
multipl
speci
includ
rabbit
rat
mice
healthi
human
donor
sampl
posit
convent
merscov
neutral
assay
remain
three
neg
tabl
neutral
titer
posit
sampl
rang
celisa
perform
neutralizationposit
sera
compet
bind
merscov
antigen
three
neutralizationneg
sera
show
neg
reaction
celisa
sensit
specif
celisa
respect
tabl
compar
percent
inhibit
valu
camel
sera
celisa
neutral
titer
signific
posit
correl
percent
inhibit
serum
dilut
celisa
neutral
titer
pearson
correl
coeffici
r
fig
also
signific
posit
correl
percent
inhibit
differ
serum
dilut
use
r
serum
dilut
mix
mab
incub
h
vero
cell
inocul
mixtur
day
viral
titer
determin
use
plaqu
form
assay
viral
titer
express
pfuml
r
serum
dilut
fig
commonli
use
elisa
iggigm
elisa
reli
speciesspecif
secondari
antibodi
detect
moreov
reduc
nonspecif
reaction
serum
sampl
treat
specif
manner
circumst
qing
et
al
disadvantag
togeth
fact
merscov
zoonot
viru
led
us
develop
celisa
approach
would
enabl
us
studi
preval
posit
merscov
antibodi
multipl
anim
speci
well
assess
risk
zoonot
infect
merscov
human
present
studi
gener
novel
mab
specif
recogn
protein
merscov
develop
celisa
basi
mab
rel
neutral
test
live
merscov
gold
standard
field
detect
antimerscov
antibodi
celisa
abl
detect
dromedari
camel
sera
posit
n
neg
n
merscovspecif
antibodi
sensit
specif
respect
moreov
celisa
abl
detect
antimerscov
antibodi
sera
merscovinfect
rat
rabbit
immun
merscov
protein
addit
neg
control
sampl
includ
sera
rabbit
mice
immun
sarscov
particl
n
protein
merscov
protein
sarscov
inhibit
bind
mab
merscov
antigen
even
lowest
serum
dilut
antisera
coronavirus
avail
studi
test
specif
celisa
use
howev
ensur
accuraci
versatil
celisa
label
mab
character
term
antigen
specif
fig
supplementari
fig
confirm
specif
celisa
high
thu
celisa
detect
merscov
antibodi
nonspeciesdepend
highlyspecif
manner
furthermor
found
three
mab
select
epitop
analys
includ
highli
specif
rbd
protein
merscov
compar
rbd
amino
acid
sequenc
strain
merscov
ncbi
databas
found
amino
acid
residu
critic
recognit
three
mab
conserv
strain
data
shown
indic
merscov
strain
report
date
like
recogn
three
mab
thu
three
mab
may
use
detect
merscovspecif
antibodi
celisa
best
knowledg
first
report
celisa
base
merscov
proteinspecif
mab
determin
put
epitop
mab
use
celisa
analyz
amino
acid
substitut
mutant
merscov
virus
escap
neutral
two
mutat
escap
virus
locat
rbd
specif
within
site
bind
human
host
receptor
mediat
infect
viru
ying
fig
abil
competit
elisa
base
monoclon
antibodi
mab
detect
merscov
proteinspecif
antibodi
infect
rat
immun
rabbit
mab
mix
serial
dilut
sera
rat
infect
merscov
two
rabbit
immun
protein
merscov
rabbit
immun
n
protein
merscov
rabbit
immun
protein
sarscov
rabbit
immun
uvinactiv
sarscov
particl
rat
mock
infect
merscov
mixtur
subject
celisa
use
whole
uvinactiv
merscov
antigen
percent
inhibit
rel
antibodi
control
obtain
three
independ
experi
express
mean
standard
deviat
shown
serum
sampl
contain
neutral
antibodi
live
merscov
shown
gray
box
posit
dromedari
camel
sera
antibodi
merscov
competit
elisa
live
merscovbas
neutral
assay
correl
percent
inhibit
competit
elisa
neutral
titer
camel
sera
determin
use
live
merscov
sixtythre
sera
dromedari
camel
ethiopia
test
variou
dilut
competit
elisa
neutral
test
percent
inhibit
sampl
dilut
competit
elisa
plot
yaxi
neutral
titer
log
plot
xaxi
pearson
correl
coeffici
r
et
al
observ
suggest
mab
react
site
rbd
respons
abil
neutral
merscov
infect
vero
cell
support
fact
celisa
serum
antibodi
inhibit
label
antibodi
either
block
label
antibodi
epitop
directli
recogn
neighbor
epitop
therefor
provid
spatial
competit
hirota
et
al
given
neutral
epitop
appear
target
competit
mab
test
serum
antibodi
like
inhibitori
serum
antibodi
detect
celisa
neutral
antibodi
celisa
differ
neutral
test
one
dromedari
camel
serum
sampl
sampl
posit
neutral
test
neg
celisa
also
signific
posit
correl
percent
inhibit
valu
celisa
neutral
titer
although
correl
coeffici
r
vari
slightli
differ
serum
dilut
studi
limit
particular
yet
test
serum
sampl
convalesc
patient
mer
valid
efficaci
celisa
serolog
diagnosi
mer
human
howev
studi
show
celisa
use
detect
merscov
antibodi
infect
immun
rat
rabbit
studi
dromedari
camel
celisa
also
advantag
perform
high
contain
laboratori
unlik
neutral
test
thu
celisa
may
use
serolog
diagnos
merscov
infect
variou
anim
speci
may
play
import
role
seroepidemiolog
investig
merscov
infect
